Target Mutagenesis Vaccine Platform for Ehrlichia and Anaplasma Vaccine Candidates
Description: Researchersat Kansas State University have discovered a new targeted mutagenesis vaccineplatform that has the potential to create attenuated live canine vaccinecandidates for Ehrlichia and Anaplasma species.Obligate intracellular bacteria (hereafter“obligates”) are responsible for causing infections and diseases in animals andhumans. The obligates include manypathogenic Gram-negative bacteria of the orders Rickettsiales andChlamydiales. Disrupting specific genefunction and subsequent restoration of its activity in obligates remainextremely challenging due to their absolute requirement for residence inside ahost cell to replicate. K-State researchers have created targeted mutationsby allelic exchange in two genes and genetically complemented one of theinactivated genes of the rickettsial pathogen Ehrlichia chaffeensis. Inprinciple, this approach can be applied to other obligate intracellular bacteria,such as other species of Ehrlichia (E.canis), Anaplasma, Rickettsia, Orientia, and Chlamydia, and will enable structure-function analyses. Advantages:Platform technology applicable to numerous obligateintracellular bacteria Applications:Canine vaccines such as E. canis, E. chaffeensis, A. phagocytophilum, A. platys, Rickettsia rickettsii(RMSF agent)Human vaccinesIntellectual Property Status: PCT application filed in April 2018.Kansas State University Research Foundation seeks to have discussions with companies that are interested in licensing and/or research collaborations.Interested parties should contact:Kansas State University Institute for Commercialization (KSU-IC)2005 Research Park Circle Manhattan, KS 66502Tel: 785-532-3900 Fax: 785-532-3909E-Mail: ic@k-state.edu
美国
